ReviewCurrent treatment options in oncology2022

The Role of PARP Inhibitors in Patients with Primary Malignant Central Nervous System Tumors.

Susan E Gueble et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.